NR3C1 and Cushing syndrome due to macronodular adrenal hyperplasia: Additionally, M3S-GRPred was applied to identify potential GR antagonists among FDA-approved drugs confirmed through molecular docking, followed by detailed MD simulation studies for drug repurposing in Cushing’s syndrome.